Gyre Therapeutics, Inc.GYRENASDAQ
Loading
Book Value/Share Growth Under PressureDecelerating
Percentile Rank62
3Y CAGR-79.2%
Year-over-Year Change
Year-over-year book value per share growth
3Y CAGR
-79.2%/yr
Quarterly compound
Percentile
P62
Within normal range
vs 3Y Ago
0x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 1.23% |
| Q3 2025 | 6.16% |
| Q2 2025 | 20.35% |
| Q1 2025 | 4.37% |
| Q4 2024 | 0.57% |
| Q3 2024 | 5.32% |
| Q2 2024 | 2.40% |
| Q1 2024 | 485.42% |
| Q4 2023 | 296.62% |
| Q3 2023 | -96.71% |
| Q2 2023 | 1.36% |
| Q1 2023 | 20.67% |
| Q4 2022 | 137.10% |
| Q3 2022 | -61.69% |
| Q2 2022 | 191.77% |
| Q1 2022 | -67.08% |
| Q4 2021 | -32.43% |
| Q3 2021 | -29.23% |
| Q2 2021 | -25.41% |
| Q1 2021 | 6.62% |
| Q4 2020 | -19.30% |
| Q3 2020 | -30.03% |
| Q2 2020 | -8.87% |
| Q1 2020 | 17.76% |
| Q4 2019 | -16.05% |
| Q3 2019 | -12.95% |
| Q2 2019 | -12.20% |
| Q1 2019 | -11.86% |
| Q4 2018 | -7.77% |
| Q3 2018 | -5.15% |
| Q2 2018 | -27.80% |
| Q1 2018 | 135.66% |
| Q4 2017 | 16.82% |
| Q3 2017 | -26.24% |
| Q2 2017 | -48.75% |
| Q1 2017 | -23.84% |
| Q4 2016 | -19.22% |
| Q3 2016 | -19.33% |
| Q2 2016 | -16.23% |
| Q1 2016 | -10.93% |